Postchemotherapy retroperitoneal lymph node dissection for patients with residual masses in metastatic pure seminoma
JNCI: Journal of the National Cancer Institute · 04.08.2026
DOI: 10.1093/jnci/djag249 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 04.08.2026. Verfasst von Viranda H Jayalath und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Center Program Grant, 2023 MSK Department of Surgery Faculty Research Award, American Cancer Society Research Scholars Grant.
Abstract (Originalsprache)
Background
Postchemotherapy retroperitoneal lymph node dissection (pcRPLND) for metastatic testicular pure seminoma may be associated with significant morbidity and should be reserved for highly select cases. We report contemporary outcomes of pcRPLND in patients with metastatic pure seminoma with the goal of better defining patient selection for surgery and exploring gaps in current postchemotherapy diagnostics.
Methods
Patients who underwent pcRPLND following ≥1 line of chemotherapy for metastatic pure seminoma at our institution between 2000 and 2024 were included. Clinicopathologic, radiographic, perioperative, and oncologic outcomes are reported stratified by chemotherapy received and indication for surgery (consolidative vs for suspected relapse).
Results
Fifty-two patients underwent pcRPLND following ≥1 line of chemotherapy, 49 in the consolidation setting and 3 for suspected retroperitoneal-only relapse. Residual viable seminoma was found at pcRPLND in 100% (3/3) among patients treated for suspected relapse, 23% (3/13) following first-line chemotherapy, and 6% (2/36) following ≥2 lines of chemotherapy. None of the 15 patients that received high-dose chemotherapy (TI-CE) had viable disease at pcRPLND. Over a median follow-up of 50 months, 5 patients relapsed, all of whom had viable residual seminoma at surgery. Of patients with residual seminoma at pcRPLND, 25% were cured with surgery alone, and 38% died from progressive disease. Conclusion(s) The risk of finding viable residual seminoma at pcRPLND varied based on surgical indication (relapse vs consolidation) and prior chemotherapy received; the benefits offered by surgery, particularly following first-line therapy, may be limited. These data underscore the importance of careful patient selection for pcRPLND and the need for better diagnostics to guide postchemotherapy management decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Förderung
- Cancer Center Program Grant
- 2023 MSK Department of Surgery Faculty Research Award
- American Cancer Society Research Scholars Grant
- NIH/NCI
Zitieren
APA
Jayalath, V. H., Gold, S. A., Liso, N., Williams, B., Funt, S. A., Feldman, D. R., Sheinfeld, J., & Matulewicz, R. S. (2026). Postchemotherapy retroperitoneal lymph node dissection for patients with residual masses in metastatic pure seminoma. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag249
Vancouver
Jayalath VH, Gold SA, Liso N, Williams B, Funt SA, Feldman DR, et al. Postchemotherapy retroperitoneal lymph node dissection for patients with residual masses in metastatic pure seminoma. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag249
BibTeX
@article{Jayalath2026,
author = {Jayalath, Viranda H and Gold, Samuel A and Liso, Nicole and Williams, Brandon and Funt, Samuel A and Feldman, Darren R and Sheinfeld, Joel and Matulewicz, Richard S},
title = {Postchemotherapy retroperitoneal lymph node dissection for patients with residual masses in metastatic pure seminoma},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djag249}
}
EUVIMED